In late 2023, headlines around the world promised “exercise in a pill.” The compound behind them was a small molecule with an unglamorous name: SLU-PP-332. It had never been near a human trial, and the data came entirely from mice. Yet the idea that a single molecule could switch on some of the same genetic machinery as a hard training session was enough to make it one of the most talked-about research chemicals of the year. This is where it came from, and what the record actually says.
What SLU-PP-332 actually is
First, a correction that matters. SLU-PP-332 is often grouped in with peptides online, but it is not a peptide. It is a synthetic small molecule from the benzohydrazide chemical class. Its job is to bind and activate a family of nuclear receptors called the estrogen-related receptors, or ERRs.
There are three of these receptors: ERRα, ERRβ and ERRγ. SLU-PP-332 is described as a pan-agonist, meaning it activates all three rather than picking out just one, with its strongest reported activity at ERRα (an EC50 in the region of 98 nM in published assays). Despite the “estrogen-related” name, ERRs do not bind estrogen. They are better understood as master regulators of how cells produce and burn energy, governing mitochondrial density and fat metabolism. That energy-control role is the whole reason the molecule became interesting.
Who developed SLU-PP-332
The compound is a product of the laboratory of Thomas Burris, a pharmacologist who has spent his career on the chemistry of nuclear receptors. The “SLU” prefix is the clue to its origins: the work began at Saint Louis University, where Burris chaired the Department of Pharmacology and Physiology. The medicinal chemistry side of the effort is associated with collaborator Bahaa Elgendy, and the underlying benzohydrazide scaffold traces back to earlier receptor-ligand patent work rather than being invented from scratch.
Burris has since moved on, later heading the University of Florida Genetics Institute, with earlier stints at Scripps Research and Washington University along the way. But the naming stuck. SLU-PP-332 carries the fingerprint of the Saint Louis University lab where it was first characterised as an ERR agonist and turned into a usable research tool for probing this branch of receptor biology.
The 2023 papers that made it famous
The molecule moved from obscure tool compound to news story on the strength of two 2023 publications, both led by Cyrielle Billon with Burris and colleagues.
The first, in ACS Chemical Biology in April 2023, carried the descriptive title “Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.” In it, mice given the compound showed changes in skeletal muscle that resembled the transcriptional signature seen after endurance exercise, including a shift toward oxidative muscle fibres and improved performance on treadmill exhaustion testing. Reported gains in running distance and time sat in the rough range of 20 to 30 percent over vehicle controls. This is the study that earned the “exercise mimetic” label.
The second, published in the Journal of Pharmacology and Experimental Therapeutics later in 2023, was titled “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” Here the interest shifted to body composition and metabolism: treated mice showed reduced fat mass without eating less, alongside signs of improved metabolic function. Together the two papers framed a single idea, that activating ERRs pharmacologically could reproduce parts of what exercise does to the body’s energy systems, at least in a mouse.
Where the science stands
It is worth being blunt about maturity. Every headline-generating result described above comes from rodent studies, often at high doses delivered by injection over short windows. There is no published human clinical data. Questions that any real drug candidate has to answer, about long-term safety, the consequences of activating ERRs system-wide, and whether any of it translates to people, remain open.
What SLU-PP-332 has genuinely earned is a place in the exercise-mimetic research conversation. It gave scientists a specific, well-characterised chemical probe for asking what ERR activation does inside a living animal, and it sharpened interest in whether the metabolic effects of physical activity can be understood, and one day perhaps mimicked, at the level of a single receptor family. That is a legitimate scientific story. The “pill that replaces the gym” version is not one the underlying data supports.
→ SLU-PP-332 Research Guide · COA available SLU-PP-332 range
Research use only. SLU-PP-332 is supplied by Vero Labs strictly as a research compound for in-vitro and laboratory investigation. It is not a dietary supplement, medicine or therapeutic product, and is not for human or animal use. This article is provided for historical and scientific context only and is not medical advice. Every batch we supply is independently third-party lab-tested, with a published Certificate of Analysis (COA) available for the material.